Publication of new Aveed data in Journal of Clinical Pharmacology; data evaluates dosing flexibility in men with hypogonadism.
The objective of this population PK analysis was to assess the potential impact of a more frequent dose regimen of testosterone undecanoate (8 weeks vs. 10 weeks) on exposure parameters of clinical interest.
The current FDA-approved recommended dose of Aveed is 3 mL (750 mg) injected intermuscularly, followed by 3 mL (750 mg) injected after 4 weeks, then 3 mL (750 mg) injected every 10 weeks thereafter. The findings from this PK model and simulation were published in The Journal of Clinical Pharmacology.
See-"Population Pharmacokinetic Modeling and Simulations to Evaluate a Potential Dose Regimen of Testosterone Undecanoate in Hypogonadal Males."-Alexander W. Pastuszak MD, PhD, Mark Bush PhD, Laura Curd MS, Saji Vijayan MBBS, D.Diab, Tony Priestley PhD, Qinfang Xiang PhD, Yiqun Hu MD, PhD First published: 16 July 2021 https://doi.org/10.1002/jcph.1939.
Related news and insights
GSK Australia is pleased to announce that the Therapeutic Goods Administration (TGA) has registered Zejula (niraparib) for the treatment of women with advanced high-grade ovarian, fallopian tube or primary peritoneal cancer following completion of first-line platinum-based chemotherapy.
Bristol-Myers Squibb K.K. announced that Japan’s Ministry of Health, Labour and Welfare has approved Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and have either experienced disease progression on the last therapy or relapse after the last therapy.